Anzeige
Mehr »
Donnerstag, 12.03.2026 - Börsentäglich über 12.000 News
Defence-Aktie übernimmt Cashflow-starken Fertiger - und baut eigene Produktionsmacht auf
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DWYX | ISIN: US19188J4094 | Ticker-Symbol: 8CC
Stuttgart
12.03.26 | 10:31
0,850 Euro
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
COCRYSTAL PHARMA INC Chart 1 Jahr
5-Tage-Chart
COCRYSTAL PHARMA INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,8500,92511:00
0,8500,92510:42

Aktuelle News zur COCRYSTAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoCocrystal Pharma, Inc. - 8-K, Current Report2
19.02.Cocrystal Pharma, Inc. - 8-K, Current Report1
15.01.Cocrystal Pharma, Inc. - 8-K, Current Report2
18.12.25Cocrystal Pharma advances norovirus drug candidate to Phase 1b trial2
18.12.25Cocrystal Pharma, Inc.: Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus212Subject enrollment expected to begin in Q1 2026CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral gastroenteritis...
► Artikel lesen
18.12.25Cocrystal Pharma, Inc. - 8-K, Current Report-
01.12.25Cocrystal Pharma, Inc. - 8-K, Current Report-
14.11.25Cocrystal Pharma, Inc. - 8-K, Current Report-
COCRYSTAL Aktie jetzt für 0€ handeln
14.11.25Cocrystal Pharma, Inc. - 10-Q, Quarterly Report-
27.10.25Cocrystal Pharma, Inc. - 8-K, Current Report12
27.10.25Cocrystal Pharma erhält NIH-Förderung in Höhe von 500.000 US-Dollar für Grippemedikament2
27.10.25Cocrystal Pharma receives $500,000 NIH grant for influenza drug3
19.09.25Cocrystal Pharma files to sell 5.74M shares of common stock for holders4
19.09.25Cocrystal Pharma, Inc. - S-1, General form for registration of securities1
15.09.25Cocrystal Pharma closes $4.7 million registered direct offering5
15.09.25Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules5
14.08.25Cocrystal Pharma, Inc.: Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs303Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE)...
► Artikel lesen
01.08.25Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression244SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ("Artelo" or the "Company") (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling...
► Artikel lesen
24.04.25Cocrystal Pharma, Inc.: Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants326Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025Cocrystal Pharma's pan-viral...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1